Exagen Inc. (NASDAQ:XGN) Short Interest Up 48.7% in October

Exagen Inc. (NASDAQ:XGN) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 23,500 shares, a growth of 48.7% from the September 30th total of 15,800 shares. Based on an average trading volume of 53,000 shares, the short-interest ratio is currently 0.4 days. Approximately 0.3% of the shares of the stock are short sold.

Exagen Trading Down 5.3 %

Shares of Exagen stock traded down $0.15 during trading on Friday, reaching $2.69. The company’s stock had a trading volume of 10,504 shares, compared to its average volume of 43,042. The company has a quick ratio of 4.32, a current ratio of 4.32 and a debt-to-equity ratio of 1.13. Exagen has a 52-week low of $1.30 and a 52-week high of $3.71. The firm’s 50-day moving average is $2.94 and its two-hundred day moving average is $2.26. The company has a market cap of $46.73 million, a price-to-earnings ratio of -2.47 and a beta of 1.32.

Exagen (NASDAQ:XGN) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.20. The business had revenue of $15.06 million during the quarter, compared to analyst estimates of $13.20 million. Exagen had a negative net margin of 30.56% and a negative return on equity of 78.90%. During the same period in the prior year, the business posted ($0.28) earnings per share. On average, sell-side analysts anticipate that Exagen will post -1.02 earnings per share for the current year.

Hedge Funds Weigh In On Exagen

A hedge fund recently bought a new stake in Exagen stock. Creative Planning bought a new position in Exagen Inc. (NASDAQ:XGN) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 35,500 shares of the company’s stock, valued at approximately $110,000. Creative Planning owned 0.20% of Exagen as of its most recent SEC filing. 75.25% of the stock is owned by institutional investors.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).